The role of staging in multiple myeloma

被引:0
|
作者
Yavorkovsky, Leonid L. [1 ]
机构
[1] Kaiser Permanente San Jose Med Ctr, Oncol Div, 271 Int Circle, San Jose, CA 95119 USA
关键词
Multiple myeloma; staging; risk stratification; prognosis; treatment; ADAPTED THERAPY MSMART; MAYO STRATIFICATION; RISK STRATIFICATION; DURIE-SALMON; R-ISS; SYSTEM; DIAGNOSIS; MANAGEMENT; CONSENSUS; SURVIVAL;
D O I
10.1080/17474086.2023.2277876
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The importance of cancer staging is determined by how accurately it can predict prognosis, and how useful it is for treatment decisions. Compared to other malignancies, multiple myeloma (MM) staging proved more challenging because of unreliable prognostic factors and wide-ranging life expectancy. As traditional MM staging continues to evolve, it requires reassessment of its prognostic and predictive value.Areas covered: The studies that included prognostic and predictive value of MM stages from 1975 through 2023 were selected for this review using PubMed, MEDLINE platforms. The history and evolution of MM staging are revisited, including its role in predicting survival, treatment planning and potential practical implications for the future. The role of MM staging for oncological practice and patient counseling is discussed.Expert opinion: The utility of the traditional MM staging remains unsatisfactory because it lacks a strong connection with the disease biology, prognosis or treatment planning. Additionally, it demonstrates a modest value for patient counseling because individual prognosis is subject to under- or overestimation, and the median survival or survival rates are difficult concepts to grasp. Although the role of MM stages may change in the future, the current research upholds the notion that MM staging benefits more medical research and clinical trials than oncological practice.
引用
收藏
页码:933 / 942
页数:10
相关论文
共 50 条
  • [1] Role of FDG PET in the staging of multiple myeloma
    Joao R. T. Vicentini
    Miriam A. Bredella
    Skeletal Radiology, 2022, 51 : 31 - 41
  • [2] Role of FDG PET in the staging of multiple myeloma
    Vicentini, Joao R. T.
    Bredella, Miriam A.
    SKELETAL RADIOLOGY, 2022, 51 (01) : 31 - 41
  • [3] Staging and prognostication of multiple myeloma
    Fonseca, Rafael
    Monge, Jorge
    Dimopoulos, Meletios A.
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (01) : 21 - 31
  • [4] Multiple Myeloma: Role of Imaging in Diagnosis, Staging, and Treatment Response Assessment
    Nassar, Sameh
    Taher, Ahmed
    Spear, Rosario
    Wang, Felicia
    Madewell, John E.
    Mujtaba, Bilal
    SEMINARS IN ULTRASOUND CT AND MRI, 2021, 42 (02) : 184 - 193
  • [5] Prognostic factors and staging in multiple myeloma
    Fonseca, Rafael
    Miguel, Jesus San
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (06) : 1115 - +
  • [6] Multiple myeloma. Epidemiology and staging
    Hillengass, J.
    Goldschmidt, H.
    ONKOLOGE, 2010, 16 (03): : 225 - +
  • [7] STAGING AND KINETICS OF MULTIPLE-MYELOMA
    DURIE, BGM
    CLINICS IN HAEMATOLOGY, 1982, 11 (01): : 3 - 18
  • [8] CLINICAL STAGING IN MULTIPLE-MYELOMA
    WOODRUFF, RK
    WADSWORTH, J
    MALPAS, JS
    TOBIAS, JS
    BRITISH JOURNAL OF HAEMATOLOGY, 1979, 42 (02) : 199 - 205
  • [9] STAGING AND THERAPY OF MULTIPLE-MYELOMA
    CASE, DC
    JOURNAL OF THE MAINE MEDICAL ASSOCIATION, 1977, 68 (10): : 350 - 351
  • [10] STAGING AND KINETICS OF MULTIPLE-MYELOMA
    DURIE, BGM
    SEMINARS IN ONCOLOGY, 1986, 13 (03) : 300 - 309